首页> 美国卫生研究院文献>Cells >hiPSCs Derived Cardiac Cells for Drug and Toxicity Screening and Disease Modeling: What Micro- Electrode-Array Analyses Can Tell Us
【2h】

hiPSCs Derived Cardiac Cells for Drug and Toxicity Screening and Disease Modeling: What Micro- Electrode-Array Analyses Can Tell Us

机译:hiPSC衍生的心脏细胞用于药物和毒性筛查和疾病建模:微电极阵列分析可以告诉我们什么

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CM) have been intensively used in drug development and disease modeling. Since iPSC-cardiomyocyte (CM) was first generated, their characterization has become a major focus of research. Multi-/micro-electrode array (MEA) systems provide a non-invasive user-friendly platform for detailed electrophysiological analysis of iPSC cardiomyocytes including drug testing to identify potential targets and the assessment of proarrhythmic risk. Here, we provide a systematical overview about the physiological and technical background of micro-electrode array measurements of iPSC-CM. We introduce the similarities and differences between action- and field potential and the advantages and drawbacks of MEA technology. In addition, we present current studies focusing on proarrhythmic side effects of novel and established compounds combining MEA systems and iPSC-CM. MEA technology will help to open a new gateway for novel therapies in cardiovascular diseases while reducing animal experiments at the same time.
机译:人类诱导的多能干细胞(iPSC)衍生的心肌细胞(CM)已被广泛用于药物开发和疾病建模。自从iPSC心肌细胞(CM)首次产生以来,其表征已成为研究的重点。多电极/微电极阵列(MEA)系统为iPSC心肌细胞的详细电生理分析提供了一个非侵入式用户友好平台,包括药物测试以识别潜在靶标和评估心律失常风险。在这里,我们提供了有关iPSC-CM微电极阵列测量的生理和技术背景的系统概述。我们介绍了动作电位和场电位之间的异同以及MEA技术的优缺点。此外,我们目前的研究集中在结合MEA系统和iPSC-CM的新型化合物的心律失常副作用上。 MEA技术将有助于为心血管疾病的新疗法打开新的途径,同时减少动物实验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号